👀 Ones to watch: The MOST undervalued stocks to buy right nowSee Undervalued Stocks

Manchester management buys $249,999 in modular medical stock

Published 2024-11-25, 07:50 p/m
MODD
-

In a recent transaction, Manchester Management Co LLC, led by CEO James E. Besser, acquired shares of Modular Medical (TASE:PMCN), Inc. (NASDAQ:MODD). The purchase involved 166,666 shares of common stock, at a price of $1.50 per share, totaling approximately $249,999. This acquisition increases Manchester Management's stake to over 3.28 million shares, reflecting their continued investment in the medical instruments and apparatus company. The transaction was reported on November 21, 2024, as part of a regulatory filing.

In other recent news, Modular Medical, Inc. has secured a U.S. patent for key aspects of its MODD1 insulin pump, a significant step forward in its intellectual property portfolio. Concurrently, the company has commenced a proof-of-concept study investigating the use of the MODD1 pump for the delivery of rapid-acting GLP-1 therapies. This follows the recent FDA clearance of the MODD1 pump for insulin delivery in adults. Furthermore, the company has received FDA approval to market its new MODD1 insulin patch pump in the United States with sales planned for early 2025.

In terms of executive compensation, the Board of Directors granted new stock options to executive officers and non-executive employees, contingent on receiving FDA clearance for the MODD1 pump. Benchmark upgraded the company's stock price target and maintained a Speculative Buy rating. The company also initiated a manufacturing transfer to Phillips Medisize facilities in Mexico, marking a significant step towards high-volume production. These are the latest developments in Modular Medical's ongoing efforts to improve access to high-standard glycemic control for people with diabetes.

InvestingPro Insights

Following Manchester Management's recent acquisition of Modular Medical, Inc. (NASDAQ:MODD) shares, investors may benefit from additional context provided by InvestingPro data and tips.

As of the latest data, MODD's market capitalization stands at $58.28 million, reflecting its current position in the medical instruments sector. The company's stock has experienced significant volatility recently, with a 23.81% decline over the past week and a 27.93% drop in the last month. This recent downturn aligns with an InvestingPro Tip indicating that the stock's RSI suggests it may be in oversold territory, potentially presenting an opportunity for value investors.

Despite the recent share price weakness, MODD has demonstrated strong long-term performance, with an InvestingPro Tip highlighting a robust return over the last five years. This long-term strength contrasts with the company's current financial challenges, as another InvestingPro Tip notes that MODD is quickly burning through cash and is not profitable over the last twelve months.

The company's Price to Book ratio of 9.29 suggests a premium valuation compared to its book value, which may be a consideration for investors assessing the stock's current price levels in light of Manchester Management's recent purchase.

For readers seeking a more comprehensive analysis, InvestingPro offers 12 additional tips for MODD, providing a deeper understanding of the company's financial health and market position.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2024 - Fusion Media Limited. All Rights Reserved.